Finance

Beta
Lists
PHIO:NASDAQ
Phio Pharmaceuticals Corp
$0.97
+1.06%
(+0.010) 1D
$0.96
-0.94% (-0.0091)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PHIO...
Open
$0.96
High
$1.00
Low
$0.96
Mkt. cap
11.27M
Avg. vol.
170.90K
Volume
141.26K
52-wk high
$4.19
52-wk low
$0.81
EPS
-$1.49
Beta
0.82
Shares outstanding
11.62M
No. of employees
6
Open
$0.96
High
$1.00
Low
$0.96
Mkt. cap
11.27M
Avg. vol.
170.90K
Volume
141.26K
52-wk high
$4.19
52-wk low
$0.81
EPS
-$1.49
Beta
0.82
Shares outstanding
11.62M
No. of employees
6
News stories
From sources across the web
Profile
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
About Phio Pharmaceuticals Corp
CEO-
Employees6
Founded2011
Headquarters-
SectorBiotechnology
Websitephiopharma.com
Analyst ratings
Based on 1 analyst giving stock ratings to PHIO in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for PHIO in the last 3 months
Highest
Current $0.97
$14.00 (+1,343.30%)
Average
$14.00 (+1,343.30%)
Lowest
$14.00 (+1,343.30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Keller
H.C. Wainwright
Buy
Reiterated
$14.00
+1,343.3%
05/08/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
1.07M
1.18M
1.48M
2.79M
Cost of revenue
1.07M
1.18M
1.48M
2.79M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.24M
1.32M
1.06M
1.37M
Operating expense
1.24M
1.32M
1.06M
1.37M
Total operating expenses
2.31M
2.50M
2.53M
4.17M
Operating income
-2.31M
-2.50M
-2.53M
-4.17M
Other non operating income
143.00K
-
-
3.00K
EBT including unusual items
-2.17M
-2.39M
-2.37M
-4.00M
EBT excluding unusual items
-2.17M
-2.39M
-2.37M
-4.00M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2.17M
-2.39M
-2.37M
-4.00M
Net profit margin
-
-
-
-
Earnings per share
-
-0.44
-0.15
-0.34
Interest and investment income
-
113.00K
163.00K
161.00K
Interest expense
-
-
-
-
Net interest expenses
-
113.00K
163.00K
161.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.31M
-2.50M
-2.53M
-4.17M
Gain or loss from assets sale
-
-
-
-3.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of PHIO
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer